Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
about
Current european regulatory perspectives on insulin analoguesRisk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study.Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?
P2860
Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@en
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@nl
type
label
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@en
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@nl
prefLabel
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@en
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@nl
P2093
P2860
P356
P1433
P1476
Insulin glargine and cancer ri ...... College of Clinical Pharmacy.
@en
P2093
Daniel M Riche
Jeffrey S Stroup
Jennifer D Goldman-Levine
Krystal L Edwards
L Brian Cross
Michael P Kane
Rosalyn S Padiyara
P2860
P304
P356
10.1592/PHCO.30.9.955
P407
P577
2010-09-01T00:00:00Z